A groundbreaking gene-edited stem cell therapy has induced remission in a patient with aggressive leukemia, marking a major advance in personalized cancer treatment, as reported in April 2026.
London, April 2, 2026 — In a medical first, a patient with treatment-resistant acute myeloid leukemia (AML) has achieved complete remission following a pioneering gene-edited stem cell therapy, according to a study published this week in The Lancet and reported by BBC News.
The 47-year-old patient, diagnosed with an aggressive form of AML unresponsive to conventional chemotherapy and bone marrow transplants, received the novel therapy at University College London Hospitals (UCLH) in January 2026, as detailed by the hospital’s press release.
Background: The Challenge of Relapsed Leukemia
Acute myeloid leukemia is a rapidly progressing cancer of the blood and bone marrow. According to Cancer Research UK, five-year survival rates for relapsed AML remain below 30%, underscoring the urgent need for new treatments.Standard therapies for AML include intensive chemotherapy and stem cell transplants. However, many patients relapse or do not respond, particularly those with high-risk genetic mutations. In this case, the patient had failed two previous transplants and multiple rounds of chemotherapy, as reported by Reuters.
Breakthrough: CRISPR Gene Editing Meets Stem Cell Transplant
The UCLH team employed CRISPR-Cas9 gene editing to modify donor stem cells, making them resistant to the patient’s immune attack and more effective at targeting leukemia cells. This approach, previously tested only in animal models, was approved for compassionate use by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in late 2025.
The donor stem cells were edited to remove the T-cell receptor, reducing the risk of graft-versus-host disease (GVHD), and to express a chimeric antigen receptor (CAR) targeting the CD33 protein, which is overexpressed in most AML cases, as described in The Lancet study.
Clinical Procedure and Monitoring
The patient underwent conditioning chemotherapy before receiving the gene-edited stem cell infusion. According to UCLH, the patient was closely monitored for infection, immune response, and early signs of GVHD.Within four weeks, bone marrow biopsies revealed complete molecular remission. No leukemia cells were detectable by highly sensitive flow cytometry and PCR, as reported by the research team in The Lancet.
Safety and Side Effects
The patient experienced mild cytokine release syndrome, a common side effect of CAR-T and CAR-NK therapies, but did not develop serious infections or GVHD. The side effects were managed with supportive care, and the patient was discharged after six weeks.Lead investigator Dr. Amira Patel stated to BBC News, “This is the first time gene-edited, CAR-expressing stem cells have been used in a human for AML. The patient’s rapid remission and manageable side effects are extremely encouraging.”
Expert Reactions and Peer Review
Independent experts have praised the study’s design and results. Dr. Michael Sweeney, a hematologist at the Mayo Clinic, told Reuters, “This case demonstrates the potential of combining gene editing and cell therapy for otherwise incurable blood cancers.”However, experts caution that a single case does not establish efficacy or safety for broader populations. Larger clinical trials are needed to confirm the therapy’s benefits and risks, as emphasized in an editorial accompanying the Lancet publication.
Implications for Cancer Treatment
The success of this case could pave the way for personalized, gene-edited therapies for other blood cancers and genetic disorders. According to the World Health Organization, over 300,000 new cases of leukemia are diagnosed globally each year, many of which are resistant to current treatments.The therapy also highlights the rapid progress in CRISPR gene editing since its first clinical use in 2020. As reported by Nature, over 50 clinical trials involving gene-edited cells are now underway worldwide.
Regulatory and Ethical Considerations
The MHRA’s decision to approve compassionate use was based on the patient’s lack of alternatives and the promising preclinical data. Bioethicists consulted by The Guardian note that rigorous oversight and informed consent are essential as gene-editing therapies move into mainstream medicine.The cost of gene-edited therapies remains high, with estimates from The Economic Times suggesting that similar treatments can exceed $500,000 per patient. Policymakers and insurers are debating how to ensure equitable access if such treatments become standard.
What’s Next: Clinical Trials and Broader Application
UCLH has announced plans to launch a phase 1 clinical trial enrolling up to 20 patients with relapsed AML later this year. The trial will assess safety, optimal dosing, and early efficacy signals, as confirmed by the hospital’s clinical research unit.Other research centers in the US, China, and Germany are preparing similar trials, focusing on different gene targets and cancer types. The coming years could see a new era of precision, gene-edited cell therapies for a range of intractable diseases.
Sources
This article is based on reports from The Lancet, BBC News, Reuters, Cancer Research UK, Nature, The Guardian, The Economic Times, and statements from University College London Hospitals.Sources: Information sourced from The Lancet, BBC News, Reuters, Cancer Research UK, Nature, The Guardian, The Economic Times, and University College London Hospitals.